A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

• Status: Recruiting
• Trial end date: 2025-08-31

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)

• Phase: Phase 3

Details

• Lead Sponsor: Hoffmann-La Roche
• Collaborators: Alliance Foundation Trials (AFT); Breast International Group; Frontier Science & Technology Research Foundation, Inc.; Frontier Science and Technology Research Foundation Inc (FS); Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)
• Treatments: Albumin-Bound Paclitaxel; Antibodies; Antibodies, Monoclonal; Atezolizumab; Cyclophosphamide; Doxorubicin; Epirubicin; Lenograstim; Liposomal doxorubicin; Paclitaxel; Taxane